Toll-like Receptor 4 Plays a Vital Role in Irritable Bowel Syndrome: a Scoping Review

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2025 Jan 3

PMID 39749341

Authors

Xuemeng Wan

Liyuan Wang

Zhiling Wang

Chaomin Wan

Affiliations

Soon will be listed here.

Abstract

Background: Irritable bowel syndrome (IBS) is a common gastrointestinal disease. Recently, an increasing number of studies have shown that Toll-like receptor 4 (TLR4), widely distributed on the surface of a variety of epithelial cells (ECs) and immune sentinel cells in the gut, plays a vital role in developing IBS.

Objectives: We sought to synthesize the existing literature on TLR4 in IBS and inform further study.

Methods: We conducted a systematic search of the PubMed, Embase (Ovid), Scopus, Web of Science, MEDLINE, and Cochrane Library databases on June 8, 2024, and screened relevant literature. Critical information was extracted, including clinical significance, relevant molecular mechanisms, and therapeutic approaches targeting TLR4 and its pathways.

Results: Clinical data showed that aberrant TLR4 expression is associated with clinical manifestations such as pain and diarrhea in IBS. Aberrant expression of TLR4 is involved in pathological processes such as intestinal inflammation, barrier damage, visceral sensitization, and dysbiosis, which may be related to TLR4, NF-κB, pro-inflammatory effects, and CRF. Several studies have shown that many promising therapeutic options (i.e., acupuncture, herbs, probiotics, hormones, etc.) have been able to improve intestinal inflammation, visceral sensitization, intestinal barrier function, intestinal flora, defecation abnormalities, and depression by inhibiting TLR4 expression and related pathways.

Conclusion: TLR4 plays a crucial role in the development of IBS. Many promising therapeutic approaches alleviate IBS through TLR4 and its pathways. Strategies for targeting TLR4 in the future may provide new ideas for treating IBS.

References

Nighot M, Al-Sadi R, Guo S, Rawat M, Nighot P, Watterson M . Lipopolysaccharide-Induced Increase in Intestinal Epithelial Tight Permeability Is Mediated by Toll-Like Receptor 4/Myeloid Differentiation Primary Response 88 (MyD88) Activation of Myosin Light Chain Kinase Expression. Am J Pathol. 2017; 187(12):2698-2710. PMC: 5718096. DOI: 10.1016/j.ajpath.2017.08.005. View

Goodoory V, Ng C, Black C, Ford A . Direct healthcare costs of Rome IV or Rome III-defined irritable bowel syndrome in the United Kingdom. Aliment Pharmacol Ther. 2022; 56(1):110-120. PMC: 9325446. DOI: 10.1111/apt.16939. View

Chaniotou Z, Giannogonas P, Theoharis S, Teli T, Gay J, Savidge T . Corticotropin-releasing factor regulates TLR4 expression in the colon and protects mice from colitis. Gastroenterology. 2010; 139(6):2083-92. DOI: 10.1053/j.gastro.2010.08.024. View

Wu M, Huang T, Huang K, Huang Y, Hung Y . Association between toll-like receptor 4 expression and symptoms of major depressive disorder. Neuropsychiatr Dis Treat. 2015; 11:1853-7. PMC: 4525784. DOI: 10.2147/NDT.S88430. View

Zheng H, Jin S, Shen Y, Peng W, Ye K, Tang T . Chinese Herbal Medicine for Irritable Bowel Syndrome: A Meta-Analysis and Trial Sequential Analysis of Randomized Controlled Trials. Front Pharmacol. 2021; 12:694741. PMC: 8353248. DOI: 10.3389/fphar.2021.694741. View

Maqoud F, Orlando A, Tricarico D, Antonacci M, Di Turi A, Giannelli G . Anti-Inflammatory Effects of a Novel Acetonitrile-Water Extract of Lens Culinaris against LPS-Induced Damage in Caco-2 Cells. Int J Mol Sci. 2024; 25(7). PMC: 11011527. DOI: 10.3390/ijms25073802. View

Rodriguez-Palma E, Velazquez-Lagunas I, Salinas-Abarca A, Vidal-Cantu G, Escoto-Rosales M, Castaneda-Corral G . Spinal alarmin HMGB1 and the activation of TLR4 lead to chronic stress-induced nociceptive hypersensitivity in rodents. Eur J Pharmacol. 2023; 952:175804. DOI: 10.1016/j.ejphar.2023.175804. View

Nebot-Vivinus M, Harkat C, Bzioueche H, Cartier C, Plichon-Dainese R, Moussa L . Multispecies probiotic protects gut barrier function in experimental models. World J Gastroenterol. 2014; 20(22):6832-43. PMC: 4051923. DOI: 10.3748/wjg.v20.i22.6832. View

Xia Y, Peng S, Lin M, Duan H, Yuan F, Shao M . Apigenin attenuates visceral hypersensitivity in water avoidance stress rats by modulating the microbiota-gut-brain axis and inhibiting mast cell activation. Biomed Pharmacother. 2023; 167:115562. DOI: 10.1016/j.biopha.2023.115562. View

10.

Kocak E, Akbal E, Koklu S, Ergul B, Can M . The Colonic Tissue Levels of TLR2, TLR4 and Nitric Oxide in Patients with Irritable Bowel Syndrome. Intern Med. 2016; 55(9):1043-8. DOI: 10.2169/internalmedicine.55.5716. View

11.

Schoultz I, Keita A . The Intestinal Barrier and Current Techniques for the Assessment of Gut Permeability. Cells. 2020; 9(8). PMC: 7463717. DOI: 10.3390/cells9081909. View

12.

Compare D, Rocco A, Coccoli P, Angrisani D, Sgamato C, Iovine B . Lactobacillus casei DG and its postbiotic reduce the inflammatory mucosal response: an ex-vivo organ culture model of post-infectious irritable bowel syndrome. BMC Gastroenterol. 2017; 17(1):53. PMC: 5391611. DOI: 10.1186/s12876-017-0605-x. View

13.

Wu I, Wong C, Ho R, Cheung W, Ford A, Wu J . Acupuncture and related therapies for treating irritable bowel syndrome: overview of systematic reviews and network meta-analysis. Therap Adv Gastroenterol. 2019; 12:1756284818820438. PMC: 6348567. DOI: 10.1177/1756284818820438. View

14.

Sperber A, Bangdiwala S, Drossman D, Ghoshal U, Simren M, Tack J . Worldwide Prevalence and Burden of Functional Gastrointestinal Disorders, Results of Rome Foundation Global Study. Gastroenterology. 2020; 160(1):99-114.e3. DOI: 10.1053/j.gastro.2020.04.014. View

15.

Brietzke E, Mansur R, Subramaniapillai M, Balanza-Martinez V, Vinberg M, Gonzalez-Pinto A . Ketogenic diet as a metabolic therapy for mood disorders: Evidence and developments. Neurosci Biobehav Rev. 2018; 94:11-16. DOI: 10.1016/j.neubiorev.2018.07.020. View

16.

Guo W, Liu P, Dong L, Wang J . [The correlation study between the changes of intestinal mucosa predominant bacteria and Toll-like receptor 2, Toll-like receptor 4 gene expressions in diarrhea-predominant irritable bowel syndrome patients]. Zhonghua Nei Ke Za Zhi. 2016; 55(7):541-3. DOI: 10.3760/cma.j.issn.0578-1426.2016.07.011. View

17.

Schaper S, Stengel A . Emotional stress responsivity of patients with IBS - a systematic review. J Psychosom Res. 2021; 153:110694. DOI: 10.1016/j.jpsychores.2021.110694. View

18.

Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell G, Santini D . Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology. 2004; 126(3):693-702. DOI: 10.1053/j.gastro.2003.11.055. View

19.

Huang H, Zhao P, Xi M, Li F, Ji L . Mechanism of QingHuaZhiXie Prescription Regulating TLR4-IECs Pathway in the Intervention of Diarrhea Predominant Irritable Bowel Syndrome. Evid Based Complement Alternat Med. 2021; 2021:5792130. PMC: 8594983. DOI: 10.1155/2021/5792130. View

20.

Polster A, Ohman L, Tap J, Derrien M, Le Neve B, Sundin J . A novel stepwise integrative analysis pipeline reveals distinct microbiota-host interactions and link to symptoms in irritable bowel syndrome. Sci Rep. 2021; 11(1):5521. PMC: 7943560. DOI: 10.1038/s41598-021-84686-9. View